Immunologically mediated dementias
- PMID: 19664365
- PMCID: PMC2832614
- DOI: 10.1007/s11910-009-0053-2
Immunologically mediated dementias
Abstract
Although most dementias are due to neurodegenerative or vascular disease, it is important to diagnose immunologically mediated dementias quickly because they can be both rapidly progressive and readily treatable. They usually affect function of limbic and cortical structures, but subcortical involvement can also occur. Because of the variety of symptoms and the rapid course, these dementias present a particular challenge to the clinician and may require evaluation and intervention in the inpatient setting. Diagnostic workup typically reveals evidence of an autoimmune process and, in some cases, cancer. In contrast to the neurodegenerative processes, many of the immunologically mediated dementias respond to immunomodulatory therapy.
Conflict of interest statement
Disclosure: No potential conflict of interest relevant to this article was reported.
References
-
- Vernino S, Geschwind MD, Boeve B. Autoimmune encephalopathies. The Neurologist. 2007;13:140–147. - PubMed
-
In this brief review of a variety of conditions, the authors focus on conditions with known antigens and antibodies.
-
- Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56:715–719. - PubMed
-
- Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–340. - PMC - PubMed
-
The authors of this updated comprehensive review discuss the diagnosis and treatment of the paraneoplastic syndromes affecting the CNS. They present organized, multifaceted tables on the syndromic diagnosis, associated antibody, and tumor in paraneoplastic disease.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical